新辅助治疗后袖状肺叶切除的生存结局
该回顾性研究纳入613例非小细胞肺癌患者,其中124例接受新辅助治疗,经1:2倾向性评分匹配后比较110例新辅助治疗与169例未接受新辅助治疗患者的生存。新辅助治疗与改善的3年无病生存率和总生存率相关,新辅助化学免疫治疗显著改善生存,而单纯化疗未见显著效果。
要点
- 新辅助治疗改善袖状肺叶切除患者的3年DFS和OS。
- 新辅助化学免疫治疗显著改善3年DFS和OS,单纯化疗无显著效果。
- 病理N2期是DFS和OS的独立不良预后因素。
核心结论
- 袖状肺叶切除前的新辅助治疗显著提高局部晚期非小细胞肺癌的无病生存率和总生存率。
研究设计与样本
- 回顾性分析613例患者,其中124例接受新辅助治疗,采用1:2倾向性评分匹配形成110例新辅助治疗组和169例对照组。
主要发现
- 新辅助治疗组3年无病生存率为73.6%,对照组为54.4%(P < .001)。
- 新辅助治疗组3年总生存率为80.9%,对照组为63.9%(P = .002)。
- 新辅助化学免疫治疗组3年无病生存率为85.3%,对照组为54.4%(P = .001);总生存率为88.2% vs 63.9%(P = .006)。
- 多变量Cox回归显示新辅助治疗是改善DFS和OS的独立预测因素,病理N2期与较差的DFS和OS独立相关。
- 新辅助治疗组亚组分析中,病理N2期是DFS的独立危险因素(风险比3.830;95%CI 1.687-8.694;P = .001),主要病理缓解是更好OS的独立预测因素(风险比0.120;95%CI 0.015-0.933;P = .043)。
临床怎么用
- 对于局部晚期非小细胞肺癌,袖状肺叶切除前可考虑新辅助治疗,尤其是化学免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study was carried out to evaluate the impact of neoadjuvant therapy on long-term survival of patients with non-small cell lung cancer undergoing sleeve lobectomy. METHODS: A total of 613 patients were retrospectively analyzed, including 124 who received neoadjuvant therapy. A 1:2 propensity score matching method was adopted to create a balanced cohort including 110 with neoadjuvant therapy and 169 without neoadjuvant therapy. Survival was estimated by the Kaplan-Meier method and compared with the log-rank test and Cox proportional hazards models. RESULTS: Neoadjuvant therapy was associated with improved 3-year disease-free survival (DFS; 73.6% vs 54.4%; P < .001) and overall survival (OS; 80.9% vs 63.9%; P = .002) compared with patients without neoadjuvant therapy. Moreover, neoadjuvant chemoimmunotherapy significantly improved 3-year DFS (85.3% vs 54.4%; P = .001) and OS (88.2% vs 63.9%; P = .006), whereas chemotherapy alone did not show a significant effect. Multivariable Cox regression analysis revealed neoadjuvant therapy to be an independent predictor of improved DFS and OS, whereas pathologic N2 stage was independently associated with poorer DFS and OS. Furthermore, subgroup analysis in the neoadjuvant arm revealed that pathologic N2 stage is an independent risk factor for DFS (hazard ratio, 3.830; 95% CI, 1.687-8.694; P = .001), and achieving major pathologic response is an independent predictor for better OS (hazard ratio, 0.120; 95% CI, 0.015-0.933; P = .043). CONCLUSIONS: Neoadjuvant therapy before sleeve lobectomy significantly increased DFS and OS in locally advanced non-small cell lung cancer. Sleeve lobectomy is advisable after neoadjuvant therapy, especially following chemoimmunotherapy.
引用
- Li X, Li Q, Yang F, et al. Survival Outcomes of Neoadjuvant Therapy Followed by Sleeve Lobectomy in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2024. PMID: 39426557. doi:10.1016/j.athoracsur.2024.09.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。